Erythromycin (DrugBank: Erythromycin)
5 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
| 36 | 表皮水疱症 | 2 |
| 164 | 眼皮膚白皮症 | 1 |
| 228 | 閉塞性細気管支炎 | 1 |
| 291 | ヒルシュスプルング病（全結腸型又は小腸型） | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02005029 (ClinicalTrials.gov) | April 2013 | 18/9/2013 | Erythromycin in Parkinson's Disease | Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics | Parkinson's Disease;Levodopa | Drug: Erythromycin;Drug: placebo | Virginia Commonwealth University | NULL | Completed | 18 Years | 80 Years | All | 18 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01340235 (ClinicalTrials.gov) | June 2011 | 11/4/2011 | Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin | Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin | Epidermolysis Bullosa | Drug: Oral erythromycin | Centre Hospitalier Universitaire de Nice | NULL | Recruiting | 6 Months | 8 Years | Both | 8 | Phase 3 | France |
| 2 | EUCTR2010-024428-10-FR (EUCTR) | 03/02/2011 | Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale | Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale | Dowling Maera's bullous epidermolysis is a génodermatose with autosomique dominant transmission owed to transfers of the genes coding for keratins. It results from it a cutaneous fragility very severe especially during the early childhood. Tetracyclines showed a certain efficiency in cases isolated probably by their anti-inflammatory action but cannot be used at the young child's. The érythromycine, used in the other inflammatory dermatosis, seems to be a good candidate for these patients. MedDRA version: 12.1;Level: LLT;Classification code 10056508;Term: Acquired epidermolysis bullosa | Trade Name: erythrocine Product Name: erythrocine oral Trade Name: erythromycine Product Name: erythrocine oral | CHU de NICE | NULL | NA | Female: yes Male: yes | 8 | Phase 2 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00467831 (ClinicalTrials.gov) | April 2007 | 28/4/2007 | Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome | Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome | Hermansky-Pudlak Syndrome (HPS);Pulmonary Fibrosis;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Metabolic Disease | Drug: Losartan;Drug: Zileuton;Drug: N-Acetylcysteine;Drug: Pravastatin;Drug: Erythromycin | National Human Genome Research Institute (NHGRI) | NULL | Terminated | 18 Years | 70 Years | All | 3 | Phase 1;Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00367419 (ClinicalTrials.gov) | November 2006 | 21/8/2006 | Use of Erythromycin in Mustard-Induced Bronchiolitis | Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans | Bronchiolitis Obliterans;Acute Obliterating Bronchiolitis | Drug: Erythromycin | Baqiyatallah Medical Sciences University | NULL | Completed | N/A | N/A | Male | Phase 4 | Iran, Islamic Republic of |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03593252 (ClinicalTrials.gov) | September 1, 2018 | 22/5/2018 | Bowel Preparation in Elective Pediatric Intestinal Surgery | Mechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery Complications | Colostomy Stoma;Ileostomy - Stoma;Jejunostomy Stoma;Hirschprung's Disease;NEC;Inflammatory Bowel Diseases;Meconium Ileus;Bowel Obstruction | Drug: Senna;Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid;Drug: Erythromycin;Drug: Kanamycin;Drug: Cefazolin;Drug: Metronidazole;Other: Nil per os | McMaster University | NULL | Not yet recruiting | 6 Months | 18 Years | All | 48 | N/A | NULL |